QTc Interval is Associated with Atrial Fibrillation in Individuals with Metabolic Syndrome Phenotype

Overview

Journal Int J Gen Med

Publisher Dove Medical Press

Specialty General Medicine

Date 2022 Jul 25

PMID 35874912

Authors

Ming-Chuan Lee

Yu-Tsang Wang

Yu-Ju Li

Ching-Yi Tsai

Su-Te Chen

Wun-Jyun Jhuang

Meng-Chi Chang

Mei-Yu Chien

Hsiang-Chun Lee

Affiliations

Soon will be listed here.

Abstract

Purpose: Manifestations of metabolic syndrome (MetS) carry risks for atrial fibrillation (AF). The study determined whether any electrocardiographic parameter can reflect increased AF risk in individuals with MetS.

Patients And Methods: From our University Hospital database, we examined the presence of AF and its correlation with MetS manifestations, renal function, lipid profiles, and electrocardiographic parameters (P wave duration, PR interval, QRS width, and QTc intervals). Between January 2008 and December 2015, data from 4479 adults (women 41.6% vs men 58.4%) were identified.

Results: The overall prevalence of AF was 12.4%, without sex differences (women, 12.8% vs men, 12.1%). Patients with AF were older (age 73.9 ± 11.8 vs non-AF 67 ± 13.5 years), with lower lipid levels (TG, total cholesterol, and LDL-cholesterol, all p < 0.0001), and at lower eGFR level (64.1 ± 30.9 vs non-AF 68.8 ± 41.4 mL/min/1.73m2, p < 0.0001). Besides, sex differences were present in all electrocardiographic parameters (all p < 0.05). Hypertension had the highest odds ratio (1.33; p = 0.026) for AF. Comparing AF to non-AF, the QTc of quartiles was significantly different (p < 0.0089). The shortest and longest QTc quartiles had an increased incidence of AF.

Conclusion: AF risk in patients with MetS phenotypes can be reflected by QTc quartiles.

Citing Articles

Prevalence of Metabolic Syndrome and Its Association with Cardiovascular Outcomes in Hospitalized Patients with Inflammatory Bowel Disease.

Njeim R, Pannala S, Zaidan N, Habib T, Rajamanuri M, Moussa E J Clin Med. 2024; 13(22).

PMID: 39598052 PMC: 11594857. DOI: 10.3390/jcm13226908.

References

Alonso A, Yin X, Roetker N, Magnani J, Kronmal R, Ellinor P . Blood lipids and the incidence of atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis and the Framingham Heart Study. J Am Heart Assoc. 2014; 3(5):e001211. PMC: 4323837. DOI: 10.1161/JAHA.114.001211. View

Hajhosseiny R, Matthews G, Lip G . Metabolic syndrome, atrial fibrillation, and stroke: Tackling an emerging epidemic. Heart Rhythm. 2015; 12(11):2332-43. DOI: 10.1016/j.hrthm.2015.06.038. View

Marcotte-Chenard A, Deshayes T, Ghachem A, Brochu M . Prevalence of the metabolic syndrome between 1999 and 2014 in the United States adult population and the impact of the 2007-2008 recession: an NHANES study. Appl Physiol Nutr Metab. 2019; 44(8):861-868. DOI: 10.1139/apnm-2018-0648. View

Mohanty S, Mohanty P, Di Biase L, Bai R, Pump A, Santangeli P . Impact of metabolic syndrome on procedural outcomes in patients with atrial fibrillation undergoing catheter ablation. J Am Coll Cardiol. 2012; 59(14):1295-301. DOI: 10.1016/j.jacc.2011.11.051. View

Kirubakaran S, Chowdhury R, Hall M, Patel P, Garratt C, Peters N . Fractionation of electrograms is caused by colocalized conduction block and connexin disorganization in the absence of fibrosis as AF becomes persistent in the goat model. Heart Rhythm. 2014; 12(2):397-408. PMC: 4315883. DOI: 10.1016/j.hrthm.2014.10.027. View

Patel C, Yan G, Antzelevitch C . Short QT syndrome: from bench to bedside. Circ Arrhythm Electrophysiol. 2010; 3(4):401-8. PMC: 2933105. DOI: 10.1161/CIRCEP.109.921056. View

Delgado C, Baweja M, Crews D, Eneanya N, Gadegbeku C, Inker L . A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. J Am Soc Nephrol. 2021; 32(12):2994-3015. PMC: 8638402. DOI: 10.1681/ASN.2021070988. View

Villafane J, Fischbach P, Gebauer R . Short QT syndrome manifesting with neonatal atrial fibrillation and bradycardia. Cardiology. 2014; 128(3):236-40. DOI: 10.1159/000360758. View

Tanner R, Baber U, Carson A, Voeks J, Brown T, Soliman E . Association of the metabolic syndrome with atrial fibrillation among United States adults (from the REasons for Geographic and Racial Differences in Stroke [REGARDS] Study). Am J Cardiol. 2011; 108(2):227-32. PMC: 3659169. DOI: 10.1016/j.amjcard.2011.03.026. View

10.

Nielsen J, Kuhl J, Pietersen A, Graff C, Lind B, Struijk J . P-wave duration and the risk of atrial fibrillation: Results from the Copenhagen ECG Study. Heart Rhythm. 2015; 12(9):1887-95. DOI: 10.1016/j.hrthm.2015.04.026. View

11.

Lin K, Cho S, Tiwari N, Bergman M, Kizer J, Palma E . Impact of metabolic syndrome on the risk of atrial fibrillation recurrence after catheter ablation: systematic review and meta-analysis. J Interv Card Electrophysiol. 2013; 39(3):211-23. PMC: 4720523. DOI: 10.1007/s10840-013-9863-x. View

12.

Polovina M, Hindricks G, Maggioni A, Piepoli M, Vardas P, Asanin M . Association of metabolic syndrome with non-thromboembolic adverse cardiac outcomes in patients with atrial fibrillation. Eur Heart J. 2018; 39(45):4030-4039. DOI: 10.1093/eurheartj/ehy446. View

13.

Veronese G, Montomoli J, Schmidt M, Horvath-Puho E, Sorensen H . Statin Use and Risk of Atrial Fibrillation or Flutter: A Population-based Case-Control Study. Am J Ther. 2013; 22(3):186-94. DOI: 10.1097/MJT.0b013e31827ab488. View

14.

Lee H, Shin S, Huang J, Lin M, Lin Y, Ke L . The role of postprandial very-low-density lipoprotein in the development of atrial remodeling in metabolic syndrome. Lipids Health Dis. 2020; 19(1):210. PMC: 7507670. DOI: 10.1186/s12944-020-01386-5. View

15.

Liu P, Wang L, Han D, Sun C, Xue X, Li G . Acquired long QT syndrome in chronic kidney disease patients. Ren Fail. 2019; 42(1):54-65. PMC: 6968512. DOI: 10.1080/0886022X.2019.1707098. View

16.

Zakeri R, Van Wagoner D, Calkins H, Wong T, Ross H, Heist E . The burden of proof: The current state of atrial fibrillation prevention and treatment trials. Heart Rhythm. 2017; 14(5):763-782. PMC: 5403606. DOI: 10.1016/j.hrthm.2017.01.032. View

17.

Fauchier L, Clementy N, Babuty D . Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials. Curr Opin Cardiol. 2012; 28(1):7-18. DOI: 10.1097/HCO.0b013e32835b0956. View

18.

Aromolaran A, Boutjdir M . Cardiac Ion Channel Regulation in Obesity and the Metabolic Syndrome: Relevance to Long QT Syndrome and Atrial Fibrillation. Front Physiol. 2017; 8:431. PMC: 5479057. DOI: 10.3389/fphys.2017.00431. View

19.

Wu E, Birnbaum H, Mareva M, Tuttle E, Castor A, Jackman W . Economic burden and co-morbidities of atrial fibrillation in a privately insured population. Curr Med Res Opin. 2005; 21(10):1693-9. DOI: 10.1185/030079905X65475. View

20.

Habboushe J, Altman C, Lip G . Time trends in use of the CHADS and CHA DS VASc scores, and the geographical and specialty uptake of these scores from a popular online clinical decision tool and medical reference. Int J Clin Pract. 2018; 73(2):e13280. DOI: 10.1111/ijcp.13280. View